Stock market news for October 12, 2026. Press releases, financial news, and business developments from public companies with ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of ...

(Nasdaq: TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted ...

So the stock is attached to a real, maturing franchise. The question is what the mRNA platform is worth, and the honest ...

Quince Therapeutics, Inc. announced that Effective as of October 8, 2026, John Militello, CPA, was appointed as Chief Financial Officer of the Company. John Militello, CPA, age 53, has served as Head ...

Guggenheimanalyst Vamil Divan maintains $Travere Therapeutic(TVTX.US)$ with a buy rating, and maintains the target price at ...

Join Us at the Blue Hope Bash to Support the Fight Against Colorectal Cancer / Blue Hope Bash Committee, cancer, colorectal ...

Pharmaceutical & Biotech Stock Introductory Series, Part 2, Episode 1 / 12 Episodes Total]IntroductionLigand Pharmaceuticals ...

In late September and early October 2026, Travere Therapeutics reported new FILSPARI® (sparsentan) data across IgA ...

(Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the ...

This is a real growth story, and FILSPARI is now the only approved medicine in its younger indication. But I rate the shares a Hold at this price. The valuation has run ahead of the evidence: roughly ...

New grant program supporting innovations in early detection and accurate diagnosis of kidney failure to be announced at summit ...